A Phase Ib, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered With Hu5F9-G4 to Patients With Acute Myeloid Leukemia
Sponsor: F. Hoffmann - La Roche Ltd
Enrolling: Male and Female Patients
IRB Number: AAAS3836
U.S. Govt. ID: NCT03922477
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The main purposes of this study are to: 1) understand the safety of atezolizumab given in combination with Hu5F9-G4 and 2) understand the way the body processes atezolizumab and Hu5F9-G4 (pharmacokinetics). This study will also be testing if the combination therapy is effective at treating relapsed or refractory acute myeloid leukemia (R/R AML). Atezolizumab in combination with Hu5F9-G4 is an experimental treatment, which means health authorities have not approved these drugs in combination for the treatment of R/R AML. In total, approximately 21 subjects with R/R AML will take part in this study.
This study is closed
Investigator
Daniel Lee, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have documented and confirmed Relapsed/Refractory Acute Myeloid Leukemia? Yes No
Are you willing and able to provide pretreatment bone marrow aspirate and biopsy? Yes No
Are you willing to provide bone marrow aspirates and biopsies during study treatment? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE